Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022
[170 Pages Report]The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.
By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period
Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.
Roche, Bio-Rad, and bioMιrieux are some of the major players in the infectious disease diagnostics market for assays, kits, & reagents.
By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period
Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.
Currently, NGS has become an important technology in drug discovery and pharmacogenomics; it has changed the way the pharmaceutical industry develops, tests, and targets new medicines. Advancements in technologies and the decreasing prices of NGS-based tests are also driving the growth of this technology.
By disease type, hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period
On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology
Hepatitis diagnostics market formed the largest share. Around 70% to 90% of the people in these regions (below 40 years of age) are reportedly suffering from the disease and around 8% to 20% are carriers of this virus. Another factor contributing to the growth of this market is the increasing adoption of advanced technologies for the diagnosis of hepatitis B.
HPV diagnostics market also formed one of the major market segment in infectious disease diagnostics market. HPV infections can be prevented, if diagnosed in the early stages. Pap tests are the most preferred tests to detect cervical cancer. Rapid HPV diagnostics and real-time PCR are the most advanced methods which have 95% sensitivity to HPV and cover a broad range of genotypes
CT/NG infections are the most common sexually transmitted diseases (STDs) worldwide. These infections lead to infertility in women and sterility in men. These individuals are more prone to other STDs such as AIDS. The increasing prevalence of CT/NG infections is a major factor driving growth in the CT/NG diagnostics market.
Other than the US, countries like Brazil, Australia, and developing countries in Latin America also have high prevalence rates of CT/NG infections.
The TB diagnostics market is primarily driven by the increased burden of this disease across the globe. In 2016, the highest number of new TB cases (45%) were reported in Asia, followed by 25% of new cases in Africa. Some of the most highly affected countries are China, Nigeria, Philippines, South Africa, India and Indonesia
Growth in the influenza market can be attributed to the rising prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza. Advancements in technologies such as PCR and proteomics and significant growth prospects in developing countries are also expected to offer growth opportunities for players in the influenza diagnostics market
By end user, Hospital/clinical laboratories segment to record the highest CAGR during the forecast period
Hospitals/clinical laboratories primarily serve to conduct tests on samples collected from inpatient and outpatient population. These laboratories perform IDD tests in order to identify or diagnose diseases and determine relevant treatments. Most of these laboratories are equipped with fully automated diagnostic instruments such as NGS, PCR and mass spectrometry for providing better medical diagnostic results to patients.
Compared to reference laboratories, hospital laboratories are more accessible and offer test results quickly. Furthermore, these laboratories provide flexibility in terms of scheduling specimen pickups. The growing patient population, increase in Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some key factors driving the growth of this end-user segment.
North America to account for the largest market size during the forecast period.
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
Market Dynamics
Driver: Increasing global prevalence of infectious diseases
The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents. Owing to this, patients receive empiric, broad-spectrum antimicrobial therapy rather than appropriate therapies. This has resulted in the emergence of super-resistant microbes.
Restraint: Inadequate reimbursements
According to MedPAC (Medicare Payment Advisory Commission), medical testing has witnessed a 40% decline in reimbursements over the past 40 years. Budgetary considerations among healthcare systems act as a major obstacle for the implementation of novel diagnostic techniques in clinical laboratories as reimbursements for these tests are low.
Medicare revised its reimbursement mechanism for some IVD tests, including infectious disease molecular tests, in 2012. Some of these molecular pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In the case of these codes, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions.
According to CMS, 75% tests will show reimbursement rate reductions under the proposed 2018 Medicare payment rate. Some of these tests include molecular tests, targeted next-generation sequencing analysis, panels of 5 to 50 genes, and cancer tests.
These reduced reimbursements are expected to adversely affect the adoption of molecular and genetic testing in the US, which will, in turn, hinder the growth of the market.
Opportunity: Growing awareness about personalized medicine
Growing patient awareness about the benefits of personalized medicine is one of the key factors resulting in the increased use of molecular diagnostics and genomics & proteomics technologies in infectious disease testing. Diagnostic tests can be used to assess the efficacy of specific therapeutic agents in particular patients. With the help of diagnostic tests, patients who suffer disproportionately severe adverse effects from a given treatment or dosage can be identified. Moreover, diagnostic tests help in determining the optimal dosages for drugs whose therapeutic effects are known to vary widely among different patient groups. The extent or progression of a disease and preventive measures can be identified in patients through diagnostic tests. With the growing demand for personalized medicine, the demand for such diagnostic tests is expected to increase globally.
One of the most widely used personalized treatment regimens includes therapeutic drug monitoring tests to select drugs for resistant HIV strains. According to a Los Angeles Times article, in a March 2012 survey conducted by the United Health Center for Health Reform & Modernization, more than 75% respondents agreed that genetic testing allowed physicians to offer personalized treatment. The survey also stated that the US annually spends USD 5 billion on genetic tests, which could reach USD 1525 billion by 2021. The growing availability of genetic and molecular diagnostic tests plays a crucial role in enabling the early detection of diseases and providing more personalized treatments; this can potentially result in substantial savings in treatment costs.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20162022 |
|
Base year considered |
2016 |
|
Forecast period |
20172022 |
|
Forecast units |
Million (USD) |
|
Segments covered |
Market, by Product & Service
Market, by Disease Type
Market, by Technology
Market, by End User
|
|
Geographies covered |
|
|
Companies covered |
Abbott Laboratories |
Key Market Players
Abbott Laboratories, Becton, Dickinson and Company, Biomιrieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific
Recent Developments
Critical questions the report answers:
- Where will all these developments take the industry in the long term?
- What are the upcoming trends for the infectious disease diagnostics market?
- Which segment provides the most opportunity for growth?
- Who are the leading vendors operating in this market?
- What are the opportunities for new market entrants?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 15)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 18)
2.1 PRIMARY DATA
2.1.1 KEY DATA FROM PRIMARY SOURCES
2.1.2 KEY INDUSTRY INSIGHTS
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4.1 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 26)
4 PREMIUM INSIGHTS (Page No. - 30)
4.1 INFECTIOUS DISEASE DIAGNOSTICS: MARKET OVERVIEW
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY AND REGION (2017)
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017 VS. 2022 (USD BILLION)
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
5 MARKET OVERVIEW (Page No. - 33)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing global prevalence of infectious diseases
5.2.1.2 Shift in focus from centralized laboratories to decentralized point-of-care testing
5.2.1.3 Growth in funding for research on infectious disease diagnostics
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursements
5.2.2.2 Rising healthcare costs limiting the use of novel diagnostic techniques
5.2.3 OPPORTUNITIES
5.2.3.1 Advances in genomics and proteomics
5.2.3.2 Growing awareness about personalized medicine
5.2.3.3 Growth opportunities in emerging markets
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 38)
6.1 INTRODUCTION
6.2 ASSAYS, KITS, & REAGENTS
6.3 INSTRUMENTS
6.4 SERVICES & SOFTWARE
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 44)
7.1 INTRODUCTION
7.1.1 IMMUNODIAGNOSTICS
7.1.2 CLINICAL MICROBIOLOGY
7.1.3 POLYMERASE CHAIN REACTION (PCR)
7.1.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
7.1.5 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
7.1.6 DNA MICROARRAY
7.1.7 OTHER TECHNOLOGIES
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 55)
8.1 INTRODUCTION
8.1.1 HEPATITIS
8.1.1.1 Hepatitis diagnostics market, by technology
8.1.2 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
8.1.3 CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA (CT/NG)
8.1.4 HOSPITAL-ACQUIRED INFECTIONS (HAIS)
8.1.5 HUMAN PAPILLOMAVIRUS (HPV)
8.1.6 TUBERCULOSIS (TB)
8.1.6.1 Tuberculosis diagnostics market, by technology
8.1.7 INFLUENZA
8.1.7.1 Influenza diagnostics market, by technology
8.1.8 OTHER INFECTIOUS DISEASES
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 68)
9.1 INTRODUCTION
9.2 HOSPITAL/CLINICAL LABORATORIES
9.3 REFERENCE LABORATORIES
9.4 PHYSICIAN OFFICES
9.5 ACADEMIC/RESEARCH INSTITUTES
9.6 OTHER END USERS
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 76)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA PACIFIC (APAC)
10.5 REST OF THE WORLD (ROW)
11 COMPETITIVE LANDSCAPE (Page No. - 98)
11.1 MARKET OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2017
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS
11.3.3 ACQUISITIONS
11.3.4 EXPANSIONS
12 COMPANY PROFILES (Page No. - 104)
(Business overview, Products offered, Recent developments, MNM view)*
12.1 ABBOTT LABORATORIES
12.2 BECTON, DICKINSON AND COMPANY
12.3 BIOMΙRIEUX SA
12.4 BIO-RAD LABORATORIES
12.5 DANAHER CORPORATION
12.6 DIASORIN
12.7 LUMINEX
12.8 MERIDIAN BIOSCIENCE
12.9 QUIDEL
12.10 ROCHE DIAGNOSTICS
12.11 SIEMENS HEALTHINEERS
12.12 THERMO FISHER SCIENTIFIC
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 161)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES (85 TABLES)
TABLE 1 NEW TESTS LAUNCHED BY KEY PLAYERS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 3 INFECTIOUS DISEASE DIAGNOSTIC ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 4 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC ASSAYS, KITS, & REAGENTS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 5 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 6 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 7 INFECTIOUS DISEASE DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 8 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 9 INFECTIOUS DISEASES DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 20152022 (USD MILLION)
TABLE 11 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 20152022 (USD MILLION)
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 20152022 (USD MILLION)
TABLE 13 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 20152022 (USD MILLION)
TABLE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION, 20152022 (USD MILLION)
TABLE 15 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 20152022 (USD MILLION)
TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 20152022 (USD MILLION)
TABLE 17 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 20152022 (USD MILLION)
TABLE 18 DNA SEQUENCING & NGS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 19 NORTH AMERICA: DNA SEQUENCING & NGS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 20152022 (USD MILLION)
TABLE 21 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY COUNTRY, 20152022 (USD MILLION)
TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 20152022 (USD MILLION)
TABLE 23 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 20152022 (USD MILLION)
TABLE 24 INFECTIOUS DISEASES DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 25 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 26 NORTH AMERICA: HEPATITIS DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 27 HEPATITIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 28 HIV DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 29 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 30 CT/NG DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 31 NORTH AMERICA: CT/NG DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 33 NORTH AMERICA: HAI DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 34 HPV DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 35 NORTH AMERICA: HPV DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 36 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 37 NORTH AMERICA: TUBERCULOSIS DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 38 TUBERCULOSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 39 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 40 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 41 INFLUENZA DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 42 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 43 NORTH AMERICA: OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 20152022 (USD MILLION)
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL/CLINICAL LABORATORIES, BY REGION, 20152022 (USD MILLION)
TABLE 46 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL/CLINICAL LABORATORIES, BY COUNTRY, 20152022 (USD MILLION)
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 20152022 (USD MILLION)
TABLE 48 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 20152022 (USD MILLION)
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY REGION, 20152022 (USD MILLION)
TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 20152022 (USD MILLION)
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC/RESEARCH INSTITUTES, BY REGION, 20152022 (USD MILLION)
TABLE 52 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC/RESEARCH INSTITUTES, BY COUNTRY, 20152022 (USD MILLION)
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 20152022 (USD MILLION)
TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 20152022 (USD MILLION)
TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 20152022 (USD MILLION)
TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 20152022 (USD MILLION)
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 58 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 59 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 60 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 62 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 63 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 64 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 66 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 67 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 68 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 69 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 72 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 73 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 74 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 75 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 76 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 77 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 20152022 (USD MILLION)
TABLE 78 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 (USD MILLION)
TABLE 79 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 20152022 (USD MILLION)
TABLE 80 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 20152022 (USD MILLION)
TABLE 81 RANK OF COMPANIES IN THE GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, 2017
TABLE 82 PRODUCT LAUNCHES, 2015-2018
TABLE 83 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2015 & 2018
TABLE 84 ACQUISITIONS, 2015-2017
TABLE 85 EXPANSIONS, 2015 TO 2017
LIST OF FIGURES (35 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION
FIGURE 6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017 VS. 2022
FIGURE 7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017 VS. 2022
FIGURE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017 VS. 2022
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 11 INCREASING PREVALENCE OF INFECTIOUS DISEASES IS A KEY DRIVER FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 12 IMMUNODIAGNOSTICS TECHNOLOGY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2017
FIGURE 13 ASSAYS, KITS & REAGENTS WILL CONTINUE TO DOMINATE THE INFECTIOUS DISEASE DIAGNOSTICS MARKET IN 2022
FIGURE 14 HOSPITALS & CLINICAL LABORATORIES ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2017
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 16 ASSAYS, KITS, & REAGENTS TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 17 IMMUNODIAGNOSTICS TO DOMINATE THE IDD MARKET DURING THE FORECAST PERIOD (20172022)
FIGURE 18 HEPATITIS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE THE IDD MARKET DURING THE FORECAST PERIOD (20172022)
FIGURE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2022 (USD MILLION)
FIGURE 20 GEOGRAPHICAL SNAPSHOT: ASIA PACIFIC TO BE THE FASTEST-GROWING REGIONAL SEGMENT IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 21 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 22 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 23 KEY DEVELOPMENTS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET BETWEEN 2013 AND 2016
FIGURE 24 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016)
FIGURE 25 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017)
FIGURE 26 BIOMΙRIEUX SA: COMPANY SNAPSHOT (2016)
FIGURE 27 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2016)
FIGURE 28 DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
FIGURE 29 DIASORIN: COMPANY SNAPSHOT (2017)
FIGURE 30 LUMINEX: COMPANY SNAPSHOT (2016)
FIGURE 31 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017)
FIGURE 32 QUIDEL: COMPANY SNAPSHOT (2016)
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
FIGURE 34 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2017)
FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)
Get in-depth analysis of the COVID-19 impact on the Infectious Disease Diagnostics Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Infectious Disease Diagnostics Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Infectious Disease Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Infectious Disease Diagnostics Market